Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1626

1.

Acute myeloid leukemia developing in a granulocyte colony-stimulating factor-mobilized stem cell donor: A case report and review of the literature.

Haddad H, Wungjiranirun M, Gergis U.

Hematol Oncol Stem Cell Ther. 2015 Jul 7. pii: S1658-3876(15)00053-9. doi: 10.1016/j.hemonc.2015.06.001. [Epub ahead of print]

2.

Monitoring Effects of Excipients, Formulation Parameters and Mutations on the High Order Structure of Filgrastim by NMR.

Aubin Y, Hodgson DJ, Thach WB, Gingras G, Sauvé S.

Pharm Res. 2015 Jun 5. [Epub ahead of print]

PMID:
26043856
3.

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.

Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.

Biol Blood Marrow Transplant. 2015 May 30. pii: S1083-8791(15)00381-X. doi: 10.1016/j.bbmt.2015.05.024. [Epub ahead of print]

PMID:
26033279
4.

A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.

Adar L, Avisar N, Lammerich A, Kleiman RB, Spiegelstein O.

Drug Des Devel Ther. 2015 May 15;9:2653-62. doi: 10.2147/DDDT.S81799. eCollection 2015.

5.

Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.

Arvedson T, O'Kelly J, Yang BB.

BioDrugs. 2015 Jun;29(3):185-98. doi: 10.1007/s40259-015-0127-4.

6.

[Recombinant granulocyte-colony stimulating factor (filgrastim): optimization of conditions of isolation and purification from inclusion body].

Kononova NV, Iakovlev AV, Zhuravko AM, Pankeev NN, Minaev SV, Bobruskin AI, Mart'ianov VA.

Bioorg Khim. 2014 Sep-Oct;40(5):550-9. Russian.

PMID:
25895350
7.

First biosimilar drug approved in the USA.

Burki TK.

Lancet Oncol. 2015 Apr;16(4):e161. doi: 10.1016/S1470-2045(15)70088-4. Epub 2015 Mar 13. No abstract available.

PMID:
25773170
8.

The effect of granulocyte-colony stimulating factor on rotator cuff healing after injury and repair.

Ross D, Maerz T, Kurdziel M, Hein J, Doshi S, Bedi A, Anderson K, Baker K.

Clin Orthop Relat Res. 2015 May;473(5):1655-64. doi: 10.1007/s11999-015-4218-9.

PMID:
25733010
9.

Biosimilar biologics: never identical but close enough.

Abi-Raad R, Smith BR.

Transfusion. 2015 Feb;55(2):229-31. doi: 10.1111/trf.12961. No abstract available.

PMID:
25683185
10.

A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.

Pietri E, Andreis D, Fabbri F, Menna C, Schirone A, Kopf B, Rocca A, Amadori D, De Giorgi U.

Oncologist. 2015 Mar;20(3):239-40. doi: 10.1634/theoncologist.2014-0326. Epub 2015 Jan 30.

11.

First biosimilar drug set to enter US market.

Ledford H.

Nature. 2015 Jan 15;517(7534):253-4. doi: 10.1038/517253a. No abstract available.

PMID:
25592512
12.

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.

Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K.

Support Care Cancer. 2015 Apr;23(4):1137-43. doi: 10.1007/s00520-014-2597-1. Epub 2015 Jan 10.

13.

Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study.

Wadhwa M, Bird C, Dougall T, Rigsby P, Bristow A, Thorpe R; participants of the study.

J Immunol Methods. 2015 Jan;416:17-28. doi: 10.1016/j.jim.2014.10.005. Epub 2014 Oct 25.

14.

Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.

Marchesi F, Cerchiara E, Dessanti ML, Gumenyuk S, Franceschini L, Palombi F, Pisani F, Romano A, Spadea A, Pupo L, Annibali O, La Malfa A, Arcese W, Mengarelli A.

Br J Haematol. 2015 Apr;169(2):293-6. doi: 10.1111/bjh.13199. Epub 2014 Nov 5. No abstract available.

PMID:
25371286
15.

Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim.

Duval C, Boucher S, Moulin JC, Gourieux B, Mauvieux L, Leveque D, Herbrecht R.

Anticancer Res. 2014 Nov;34(11):6747-8.

PMID:
25368285
16.

Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.

Fagnani D, Isa L, Verga MF, Nova P, Casartelli C, Filipazzi V, Danova M, Farina G, Pugliese P, Fava S, Bertolini A, Cimminiello C, Boracchi P, Marano G, Panzarino C; POLONORD Group.

Tumori. 2014 Sep-Oct;100(5):491-8. doi: 10.1700/1660.18158.

17.

Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.

Sveikata A, Gumbrevičius G, Seštakauskas K, Kregždytė R, Janulionis V, Fokas V.

Medicina (Kaunas). 2014;50(3):144-9. doi: 10.1016/j.medici.2014.08.001. Epub 2014 Aug 13.

18.

Biosimilars: the science of extrapolation.

Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK.

Blood. 2014 Nov 20;124(22):3191-6. doi: 10.1182/blood-2014-06-583617. Epub 2014 Oct 8.

PMID:
25298038
19.

[Experiences with price competition of biosimilar drugs in Hungary].

Hornyák L, Nagy Z, Tálos Z, Endrei D, Ágoston I, Csákvári T, Boncz I.

Acta Pharm Hung. 2014;84(2):83-7. Hungarian.

PMID:
25167704
20.

Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.

Kam G, Yiu R, Loh Y, Ang AL, Yueh LL, Goh YT, Wong GC.

Support Care Cancer. 2015 Mar;23(3):643-9. doi: 10.1007/s00520-014-2417-7. Epub 2014 Aug 27. No abstract available.

PMID:
25160495
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk